Company Profile

Indivior Stock Price, News & Analysis

United StatesBiotechnologyNASDAQ

Company overview

Business overview

Indivior is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Indivior is followed within the biotech universe for its exposure to catalyst-driven execution.

Business Model Characteristics

Indivior follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

Position Within the Biotechnology Landscape

Compared with more mature healthcare peers, Indivior sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

Why the stock is moving

INDV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Future catalysts

Indivior’s catalysts are Sublocade execution, opioid-use-disorder growth, and any portfolio update that helps the company keep expanding. The company moves on steady commercial execution.

Recent news

The five most recent feed items are shown below in reverse chronological order.

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.